Скачать презентацию the Future is here now The Скачать презентацию the Future is here now The

1a4e4545eb9f4ad24a0e4eac564b96de.ppt

  • Количество слайдов: 18

the Future is here & now the Future is here & now

The Therapeutic development has two hearts and one soul The Therapeutic development has two hearts and one soul

for critical care staff • The simplicity of using one single system for the for critical care staff • The simplicity of using one single system for the widest variety of treatments • The serenity of automated and simple management of complex treatments 24 h/24 h. • The reduction and optimization of the number and time of the operation

for Clinicians • A big and important therapeutic choice • An advanced and targeted for Clinicians • A big and important therapeutic choice • An advanced and targeted personalization capability • Complete control of therapeutic process

Critical Care Strategy ALI CPFA AKI MOF Multi-organ failure ABYLCAP SEPSIS SIRS HYPERCHOLESTEROLEMIA RRT: Critical Care Strategy ALI CPFA AKI MOF Multi-organ failure ABYLCAP SEPSIS SIRS HYPERCHOLESTEROLEMIA RRT: CVVHD DEGENERATIVE MACULOPATHIES DIABETIC FOOT RHEUMATOID ARTHRITIS IHF/HVHF GRAVIS MYASTHENIA GUILLAIN-BARRÈ SYNDROME IHD/SLED GLOMERULONEPHRITIS CVVHDF IHDF SCUF CVVH ABYLCAP HD Liver Failure CASCADE ARDS PEX Specific and effective therapies many diseases in ONE equipment

The Amplya Therapies COMPLETENESS Specific Sorbents ABYLCAP CPFA RRT: SCUF CVVH IHF/HVHF CVVHD IHD/SLED The Amplya Therapies COMPLETENESS Specific Sorbents ABYLCAP CPFA RRT: SCUF CVVH IHF/HVHF CVVHD IHD/SLED CVVHDF IHDF ABYLCAP HD CASCADE PEX

COMPLETENESS CPFA with Citrate Post dilution Ca. Cl 10% Uf Hemofilter Mediasorb Citrate Plasmafilter COMPLETENESS CPFA with Citrate Post dilution Ca. Cl 10% Uf Hemofilter Mediasorb Citrate Plasmafilter

AUTOMATION Personalized CPFA management with controlled servo-assisted flow COMPACT study results Mortality rate in-hospital AUTOMATION Personalized CPFA management with controlled servo-assisted flow COMPACT study results Mortality rate in-hospital and in Intensive Care units for CPFA dose in 3 days of treatment In-hospital Intensive Care Mortality controls Tertiles CPFA dose (L/Kg) The study explain that if we perform the CPFA with right dose of plasma, the mortality change from. 55, 2% Vs 25, 8% Relative Risk= 46%

COMPLETENESS The Amplya Therapies ABYLCAP CPFA RRT: SCUF CVVH IHF/HVHF CVVHD IHD/SLED CVVHDF IHDF COMPLETENESS The Amplya Therapies ABYLCAP CPFA RRT: SCUF CVVH IHF/HVHF CVVHD IHD/SLED CVVHDF IHDF ABYLCAP HD CASCADE PEX

CASCADE FILTRATION For the removal of : PLASMAFILTRO • CIC (Circulating Immune Complexes) • CASCADE FILTRATION For the removal of : PLASMAFILTRO • CIC (Circulating Immune Complexes) • Ig. M • Ig. G • Triglycerides • Lipoproteins In case of: • Hypercholesterolemia • Degenerative maculopathies • Diabetic foot • Rheumatoid arthritis • Myasthenia Gravis • Guillain-Barrè Syndrome.

CASCADE Rinsing LIQUIDO DI LAVAGGIO PLASMAFILTRO CASCADE Rinsing LIQUIDO DI LAVAGGIO PLASMAFILTRO

COMPLETENESS The Amplya Therapies ABYLCAP CPFA RRT: SCUF CVVH IHF/HVHF CVVHD IHD/SLED CVVHDF IHDF COMPLETENESS The Amplya Therapies ABYLCAP CPFA RRT: SCUF CVVH IHF/HVHF CVVHD IHD/SLED CVVHDF IHDF ABYLCAP HD CASCADE PEX

HD O 2 Dialysate flow Uf CO 2 HD O 2 Dialysate flow Uf CO 2

Multiorgan Dysfunction: many medical devices? Multiorgan Dysfunction: many medical devices?